SCHEMBL19867071

SCHEMBL19867071

COc1ccc(C(C)Nc2ccccc2)c(Cl)c1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
ALDH1A1 P00352 6/20 0.44
TDP1 Q9NUW8 3/20 0.40
GAA P10253 2/20 0.40
KDM4E B2RXH2 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
HPGD P15428 2/20 0.40
LMNA P02545 3/20 0.36
KCNK3 O14649 1/20 0.36
KCNK9 Q9NPC2 1/20 0.36
CLCN2 P51788 1/20 0.36
CYP3A4 P08684 1/20 0.36
THRB P10828 1/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
ALOX12 P18054 1/20 0.36
RECQL P46063 1/20 0.36
ATM Q13315 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10933460 0.80 CA1 (0.53) MEN1KMT2AALDH1A1TDP1GAA
SCHEMBL15713204 0.74 CA1 (0.43) KMT2AALDH1A1GAAKDM4ELMNA
SCHEMBL11829957 0.73 PTGS1 (0.48) KMT2AKDM4EL3MBTL1HPGDLMNA
SCHEMBL25786453 0.71 ALDH1A1 (0.50) MEN1KMT2AALDH1A1TDP1GAA
SCHEMBL12075070 0.71 ALDH1A1 (0.40) MEN1KMT2AALDH1A1GAAKDM4E
SCHEMBL12061499 0.71 CYP2D6 (0.47) MEN1KMT2AALDH1A1KDM4ELMNA
SCHEMBL19398867 0.71 CYP2D6 (0.47) MEN1KMT2AALDH1A1KDM4ELMNA
SCHEMBL3054988 0.70 CA1 (0.46) MEN1KMT2AALDH1A1TDP1GAA
SCHEMBL14339474 0.69 KDM4E (0.50) KMT2AALDH1A1KDM4EL3MBTL1HPGD
SCHEMBL7324255 0.68 POLB (0.49) MEN1KMT2AALDH1A1TDP1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407390-B2 Asymmetric ureas and medical uses thereof HELSINN HEALTHCARE SA 2019-09-10 US disclosed
US-20180044293-A1 ASYMMETRIC UREAS AND MEDICAL USES THEREOF HELSINN HEALTHCARE SA (CH) 2018-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10407390-B2 Asymmetric ureas and medical uses thereof UTS2R, GPR119, GHSR MEN1 2178/4885KMT2A 4280/4885ALDH1A1 1976/4885
US-20180044293-A1 ASYMMETRIC UREAS AND MEDICAL USES THEREOF UTS2R, GPR119, GHSR MEN1 2178/4885KMT2A 4280/4885ALDH1A1 1976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.